JPS6336789A - Production of coenzyme q10 - Google Patents
Production of coenzyme q10Info
- Publication number
- JPS6336789A JPS6336789A JP61176705A JP17670586A JPS6336789A JP S6336789 A JPS6336789 A JP S6336789A JP 61176705 A JP61176705 A JP 61176705A JP 17670586 A JP17670586 A JP 17670586A JP S6336789 A JPS6336789 A JP S6336789A
- Authority
- JP
- Japan
- Prior art keywords
- coenzyme
- medium
- genus
- mold
- bacterial cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title abstract description 21
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 230000001580 bacterial effect Effects 0.000 claims description 19
- 239000005515 coenzyme Substances 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 abstract description 20
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 abstract description 10
- 229940110767 coenzyme Q10 Drugs 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 5
- 108091006149 Electron carriers Proteins 0.000 abstract description 2
- 206010014561 Emphysema Diseases 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000004217 heart function Effects 0.000 abstract description 2
- 210000002345 respiratory system Anatomy 0.000 abstract description 2
- 241000862981 Hyphomonas Species 0.000 abstract 4
- 241001601725 Sthenias Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000013535 sea water Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 1
- 241000556533 uncultured marine bacterium Species 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、補酵素Q、。の製造法に関し、さらに詳細に
は、微生物を使用した補酵素QIoの製造法に係わる。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention provides coenzyme Q. More specifically, the present invention relates to a method for producing coenzyme QIo using microorganisms.
補酵素Q、。は次に示される構造式を有し、生体内の末
端呼吸系の電子伝達体として重要な役割を果たし、心臓
機能亢進剤5型症筋無力症治療剤。Coenzyme Q. has the structural formula shown below, plays an important role as an electron carrier in the terminal respiratory system in vivo, and is a cardiac function enhancer and a therapeutic agent for type 5 myasthenia.
肺気腫治療剤、再生不良性貧血治療剤および円形脱毛症
治療剤などの医薬品ならびに飼料添加剤などとして有用
な化合物である。It is a compound useful as a pharmaceutical agent such as a treatment for emphysema, a treatment for aplastic anemia, and a treatment for alopecia areata, as well as a feed additive.
〔従来の技術1発明が解決しようとする問題点〕従来、
補酵素Q10は、動物または植物の組織から抽出し、さ
らに、精製することにより製造されている。また、近年
、微生物を培養して得られた菌体より補酵素Q、。を抽
出する方法も知られている。[Prior art 1 Problems to be solved by the invention] Conventionally,
Coenzyme Q10 is produced by extracting from animal or plant tissue and further purifying it. In addition, in recent years, coenzyme Q has been produced from bacterial cells obtained by culturing microorganisms. There are also known methods for extracting.
しかしながら、微生物の補酵素Q10の生産性は未だ十
分ではなく、補酵素Q、。の生産性の大きい微生物の発
見が望まれている。However, the productivity of coenzyme Q10 by microorganisms is still not sufficient; The discovery of microorganisms with high productivity is desired.
本発明者らは、補酵素QI6の生産性の大きい微生物の
取得を目的とした。The present inventors aimed to obtain a microorganism with high productivity of coenzyme QI6.
〔問題を解決するための手段9作用〕
本発明者らは、補酵素Q+oを多星に生産する菌株を見
出すべく研究を重ねた結果、ハイホモナス属に属する菌
株が補酵素QI0を多重に生産することを見出し、本発
明に到達した。[Means for Solving the Problem 9 Effects] As a result of repeated research to find a strain that produces coenzyme Q+o in multiple ways, the present inventors found that a strain belonging to the genus Hyhomonas produces multiple coenzyme QI0. They discovered this and arrived at the present invention.
すなわち、本発明は、ハイホモナス属に属する補酵素Q
10生産細菌を培養して菌体を得、得られた菌体から補
酵素Q、。を分離回収することを特徴とする補酵素Q1
0の製造法である。That is, the present invention provides coenzyme Q belonging to the genus Hyhomonas.
10. Culture the producing bacteria to obtain bacterial cells, and from the obtained bacterial cells, coenzyme Q. Coenzyme Q1 characterized by separating and recovering
0 manufacturing method.
本発明に用いられる細菌は、ハイホモナス属に属する菌
株であれば、いずれの菌株でよいが、ハイホモナス ジ
アナシイアナ(Ilyphomonas jana−s
hiana)に属する菌株が好ましい。この代表的な菌
株としては、たとえば、ハイホモナス ジアナシイアナ
ATCC33883がある。ハイホモナス ジアナシイ
アナは海洋性細菌としてしられており、その菌学的性質
は、In5t、J、5yst、Bacteriol、、
νol。The bacteria used in the present invention may be any strain as long as it belongs to the genus Hyhomonas, but Ilyhomonas jana-s
Bacterial strains belonging to P. hiana) are preferred. A representative strain of this strain is, for example, Hyhomonas diana siana ATCC33883. Hyhomonas zianasiana is known as a marine bacterium, and its mycological properties include In5t, J, 5yst, Bacteriol,
vol.
35、 NO,3,P、237〜243 (1985)
に記載されている。35, NO, 3, P, 237-243 (1985)
It is described in.
培養に使用される培地としては、これらの補酵素Q、。As the medium used for culture, these coenzyme Q.
生産菌を増殖させるものであれば特に制限はなく、天然
培地または合成培地のどちらでもよい。There is no particular restriction on the medium as long as it allows production bacteria to grow, and it may be either a natural medium or a synthetic medium.
なお、ハイホモナス ジアナシイアナは、ポリペプトン
、酵母エキスなどを含有する海水培地またはこの培地に
おいて海水のかわりに塩化ナトリ・クム濃度が2〜6w
t%の塩化ナトリウム水溶液を使用した培地が好ましい
。In addition, Hyhomonas diana siana is grown in a seawater medium containing polypeptone, yeast extract, etc., or in this medium, the concentration of sodium chloride and cum is 2 to 6 w instead of seawater.
A medium using a t% aqueous sodium chloride solution is preferred.
培養条件については、通常は、培養温度は20〜40℃
の範囲で、また、培養pl+は6〜8の範囲で、各菌株
にとって、生育、増殖に適した温度およびpl+をそれ
ぞれ選択すればよい。Regarding culture conditions, the culture temperature is usually 20 to 40°C.
In addition, the culture pl+ may be in the range of 6 to 8, and the temperature and pl+ suitable for growth and proliferation may be selected for each strain.
培養方式は、回分培養または連続培養のいずれでもよい
。The culture method may be either batch culture or continuous culture.
細菌を培養して得られた培養液から菌体を分離、回収す
る。菌体の分離、回収には、それ自体公知の固液分離手
段が採用される。たとえば、培養液をそのまま遠心分離
する方法、培養液中の目的とする細菌よりも大きい他の
微生物の細胞を濾過助剤として加えたり、もしくは、プ
レコートすることにより培養液から菌体を濾過分離する
方法、培養液に凝集剤を加えて菌体を凝集させ、これを
濾過または遠心分離により分離する方法または、培養液
のphiを5以下にするとともに50〜100°Cで加
熱することにより菌体を凝集させて、この凝集菌体を分
離する方法などを適用しうる。分離されたままの菌体、
または、たとえば、噴霧乾燥機などによる乾燥菌体から
補酵素Q、。を抽出し、さらにこの補酵素Q10は精製
される。The bacterial cells are separated and collected from the culture solution obtained by culturing the bacteria. A known solid-liquid separation means is used to separate and recover the bacterial cells. For example, the culture solution may be centrifuged as is, cells of other microorganisms larger than the target bacteria in the culture solution may be added as a filter aid, or cells may be filtered and separated from the culture solution by pre-coating. A method is to add a flocculant to the culture solution to agglutinate the bacterial cells and separate them by filtration or centrifugation, or to reduce the phi of the culture solution to 5 or less and heat the bacterial cells at 50 to 100°C. A method of agglutinating bacteria and separating the aggregated bacterial cells can be applied. Bacterial cells that remain isolated,
Or, for example, coenzyme Q from dried bacterial cells using a spray dryer or the like. This coenzyme Q10 is further purified.
補酵素Q、。の分離、抽出および精製は、補酵素QIo
に適用されている通常の分離抽出法および精製法に従っ
て行うことができる。すなわち、たとえば、エタノール
、メタノールもしくはアセトンに菌体を)ワ、濁させて
、50〜90°Cで1〜数時間加熱して抽出して抽出液
を得る。もしくは、まず、メタノール、水酸化ナトリウ
ムおよびピロガロールの混合物を用いて、菌体中のりん
脂質などのけん化性物質をけん化してけん化成を得る。Coenzyme Q. The separation, extraction and purification of coenzyme QIo
It can be carried out according to the usual separation extraction method and purification method applied to. That is, for example, the bacterial cells are made cloudy in ethanol, methanol, or acetone, and extracted by heating at 50 to 90°C for one to several hours to obtain an extract. Alternatively, first, saponifiable substances such as phospholipids in the bacterial cells are saponified using a mixture of methanol, sodium hydroxide, and pyrogallol to obtain a saponified substance.
これらの抽出ンiもしくはけん化成から、たとえば、n
−ヘキサンのような有m?3媒によって補酵素QIOを
抽出して抽出物を得る。ついで、この抽出物から、たと
えば、ハ・fポーラスポリマーのような多孔性合成樹脂
、シリカゲルおよびフロリジルなどを用いて、補酵素Q
IOを分別、昨離し、精製する。From these extractions or saponification, for example, n
-Is it like hexane? Coenzyme QIO is extracted with three medium to obtain an extract. Next, coenzyme Q is extracted from this extract using, for example, a porous synthetic resin such as Ha.f porous polymer, silica gel, and florisil.
The IO is separated, separated and purified.
菌体から得られた補酵素QIOの同定、定量には、一般
に、高速液体クロマトグラフィー、元素分析。High performance liquid chromatography and elemental analysis are generally used to identify and quantify coenzyme QIO obtained from bacterial cells.
融点測定、赤外部吸収スペクトル、紫外部吸収スペクト
ル、核磁気共鳴スペクトルおよび質量分析などの手段が
それぞれ用いられる。Means such as melting point measurement, infrared absorption spectroscopy, ultraviolet absorption spectroscopy, nuclear magnetic resonance spectroscopy, and mass spectrometry are used.
実施例によって本発明をさらに具体的に説明する。なお
、本発明は実施例によって限定されるものではない。The present invention will be explained in more detail with reference to Examples. Note that the present invention is not limited to the examples.
実施例
純水11当たり、ペプトン5g、酵母エキス1g、<え
ん酸第二鉄0.1 g 、 NaCl 19.45 g
4MgC1z・611z08.8g 、 NazSO
n4011zO3,24g 、 CaCIz・611z
O1,8gおよびKCl0.55gを溶解し、p)l
7.6に調整された培地20On+7容三角フラスコに
入れ、120°Cで20分間高圧殺菌した。Example per pure water 11: 5 g of peptone, 1 g of yeast extract, 0.1 g of ferric citrate, 19.45 g of NaCl
4MgC1z・611z08.8g, NazSO
n4011zO3,24g, CaCIz・611z
Dissolve 1.8 g of O and 0.55 g of KCl, p)l
The medium was placed in a 20 On + 7 volume Erlenmeyer flask adjusted to 7.6 and autoclaved at 120°C for 20 minutes.
この培地に、この培地と同し組成の培地で2日間前培養
して得られたハイホモナス ジアナンイアナ ATCC
33883の前培養液を1容■%となるように植苗し、
30℃で回転振とう培養を行った。培養開始後48時間
で培養を終了し、得られた培養液を遠心分離して、菌体
を得た。Hyhomonas diananiana ATCC obtained by pre-cultivating this medium for 2 days with a medium having the same composition as this medium.
33883 preculture solution to 1 volume ■%, seedlings were planted,
Rotary shaking culture was performed at 30°C. The culture was terminated 48 hours after the start of the culture, and the resulting culture solution was centrifuged to obtain bacterial cells.
この菌体から補酵素QIGをイソプロパツール濃度90
νolχのイソプロパツール水溶液で抽出し、ついで、
ヘキサン溶液
液中の5元型補酵素Q10を硝酸鉄で酸化したのら、こ
のヘキサン溶液について、高速液体クロマトグラフィー
で補酵素QIOを同定し、その含量を測定した。Coenzyme QIG is extracted from this bacterial cell at a concentration of 90% isopropanol.
Extract with isopropanol aqueous solution of νolχ, then
After oxidizing the pentagonal coenzyme Q10 in the hexane solution with iron nitrate, coenzyme QIO was identified in the hexane solution by high performance liquid chromatography, and its content was measured.
その結果、乾燥菌体1g当たり1.50■の補酵素QI
Qが得られた。As a result, 1.50 μ of coenzyme QI per 1 g of dry bacterial cells
Q was obtained.
本発明によれば、細菌を利用して、補酵素Ok+。 According to the present invention, coenzyme Ok+ is produced using bacteria.
を容易に、かつ、安定して製造することが可能となる。can be manufactured easily and stably.
特に、細菌としてハイホモナス ジアナシイアナを使用
したときには、培地の水として海水を使用できる利点が
ある。In particular, when Hyhomonas diana siana is used as the bacterium, there is an advantage that seawater can be used as the water for the culture medium.
Claims (1)
養して菌体を得、得られた菌体から補酵素Q_1_0を
分離回収することを特徴とする補酵素Q_1_0の製造
法A method for producing coenzyme Q_1_0, characterized by culturing coenzyme Q_1_0-producing bacteria belonging to the genus Hyhomonas to obtain bacterial cells, and separating and recovering coenzyme Q_1_0 from the obtained bacterial cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61176705A JPS6336789A (en) | 1986-07-29 | 1986-07-29 | Production of coenzyme q10 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61176705A JPS6336789A (en) | 1986-07-29 | 1986-07-29 | Production of coenzyme q10 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6336789A true JPS6336789A (en) | 1988-02-17 |
Family
ID=16018308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61176705A Pending JPS6336789A (en) | 1986-07-29 | 1986-07-29 | Production of coenzyme q10 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6336789A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035658A3 (en) * | 1997-02-12 | 1999-01-21 | Mse Pharmazeutika Gmbh | The use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
CN1308455C (en) * | 2002-07-25 | 2007-04-04 | 协和发酵工业株式会社 | Process for producing solution containing ubiquinone-10 |
JP2008253271A (en) * | 2001-12-27 | 2008-10-23 | Kaneka Corp | Method for producing coenzyme q10 |
WO2019208676A1 (en) * | 2018-04-27 | 2019-10-31 | 株式会社カネカ | Method for producing coenzyme q10 |
-
1986
- 1986-07-29 JP JP61176705A patent/JPS6336789A/en active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035658A3 (en) * | 1997-02-12 | 1999-01-21 | Mse Pharmazeutika Gmbh | The use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
US6228891B1 (en) | 1997-02-12 | 2001-05-08 | Mse Pharmazeutika Gmbh | Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
JP2008253271A (en) * | 2001-12-27 | 2008-10-23 | Kaneka Corp | Method for producing coenzyme q10 |
JP2012157360A (en) * | 2001-12-27 | 2012-08-23 | Kaneka Corp | Processes for producing coenzyme q10 |
US9315839B2 (en) | 2001-12-27 | 2016-04-19 | Kaneka Corporation | Processes for producing coenzyme Q10 |
US9926580B2 (en) | 2001-12-27 | 2018-03-27 | Kaneka Corporation | Process for producing coenzyme Q10 |
CN1308455C (en) * | 2002-07-25 | 2007-04-04 | 协和发酵工业株式会社 | Process for producing solution containing ubiquinone-10 |
WO2019208676A1 (en) * | 2018-04-27 | 2019-10-31 | 株式会社カネカ | Method for producing coenzyme q10 |
JPWO2019208676A1 (en) * | 2018-04-27 | 2021-05-13 | 株式会社カネカ | Method for producing coenzyme Q10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS62282579A (en) | Antibiotic a/16686 producing bacteria | |
Kluyver et al. | Note on the biochemical preparation of inosose | |
HU211052B (en) | Method for preparing 2-aryl-propionic acids in stereo-specific form, pharmaceutical compositions containing them and microorganisms for preparation | |
JPS6336789A (en) | Production of coenzyme q10 | |
JPH01168292A (en) | Production of d-glyceric acid | |
JPS62190095A (en) | Production of coenzyme q11 | |
JPS6283894A (en) | Production of coenzyme q11 | |
JP2001008694A (en) | Novel process for producing d-chiro-inositol | |
JPS5923794B2 (en) | Manufacturing method of dihydroxyacetone | |
JPS6283895A (en) | Production of coenzyme q10 | |
JP4262528B2 (en) | (-)-Method for producing Vivo-Quercitol | |
JPH0740951B2 (en) | Method for producing hydroxide of nitrogen-containing heterocyclic compound by microorganism | |
JP2729285B2 (en) | Purification method of sorbic acid | |
JPS6015318B2 (en) | New antibiotic SF-1942 substance, its manufacturing method and anticancer agent containing it | |
JPH04304894A (en) | Production of hydroxide of picolinic acid or pyrazinic acid by microorganism | |
JPS58146291A (en) | Preparation of s-adenosylmethionine | |
KR790001337B1 (en) | Process for preparing new antibiotic gardimycin | |
JPS5830038B2 (en) | Production method of coenzyme Q↓1↓0 | |
JPH01252295A (en) | Production of 2,3-dicyano-5,6-dicyanopurazine | |
JPS61285993A (en) | Production of phenacyl alcohol | |
JPS61212587A (en) | G0069lambda substance | |
JPS5853917B2 (en) | Production method of coenzyme Q | |
JPH0323159B2 (en) | ||
JPS5899494A (en) | Novel antibiotic substance mm-240 | |
JPS59179092A (en) | 3(2-substituted-oxazol-5-yl)indole, its salt and their preparation |